Author

S. C. Purdy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

M. Wendt· 2 shared A. Basudan· 1 shared A. Chung· 1 shared A. Elangovan· 1 shared A. Ganesan· 1 shared Adrian V Lee· 1 shared C. Brisken· 1 shared C. Meier· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Wendt

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model

A. Elangovan, E. A. Bossart, A. Basudan, N. Tasdemir, O. S. Shah, K. Ding, S. C. Purdy, C. Meier, T. Heim, C. Neumann, S. Attaran, L. Brown, J. Hooda, L. Miller, K. Kota, , S. Oesterreich

The paper introduces a new invasive lobular carcinoma cell line, WCRC-25, and demonstrates its molecular features and therapeutic response to PI3K/AKT inhibition.

bioRxiv · Sep 15, 2023 · PreprintCancer Biology

The interferon/STAT1 signaling axis is a common feature of tumor-initiating cells in breast cancer

E. P. Souto, P. Gong, J. D. Landua, R. R. Srinivasan, A. Ganesan, L. E. Dobrolecki, S. C. Purdy, X. Pan, M. Zeosky, A. Chung, S. S. Yi, H. L. Ford, M. T. Lewis

The paper identifies an IFN/STAT1 transcriptional state in tumor-initiating cells (TIC) of breast cancer using single-cell RNA sequencing, showing it differs from bulk RNA-seq derived TIC signatures.

bioRxiv · Sep 15, 2023 · PreprintCancer Biology

Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy

S. S. Akhand, S. C. Purdy, Z. Liu, J. Anderson, C. Willey, M. Wendt

This study shows that FGFR1 promotes T-DM1 resistance and tumor recurrence in HER2+ breast cancer, suggesting FGFR inhibitors like FIIN4 could be combined with T-DM1 for better treatment.

bioRxiv · Aug 9, 2019Cancer Biology

Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand

R. Ali, W. Brown, S. C. Purdy, V. J. Davisson, M. Wendt

This paper shows that in metastatic breast cancer, EGFR signaling is biased toward STAT1, leading to apoptosis, and that pharmacological biasing can enhance this effect.

bioRxiv · Jun 20, 2018Cancer Biology